A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: Effects on bone mineral density and bone markers

Journal of Bone and Mineral Research

Volumn 17, Issue 3, 2002, Pages 521-527

  Trovas, G P ^a   Lyritis, G P ^a   Galanos, A ^a   Raptou, P ^a   Constantelou, E ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b Public Hospital   (Greece)

Author keywords

Bone densitometry; Bone markers; Bone turnover; Calcitonin; Osteoporosis in men

Indexed keywords

BIOCHEMICAL MARKER; CALCIUM; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; PLACEBO; PROCOLLAGEN; SALCATONIN;

ADULT; AEROSOL; AGED; ARTICLE; BONE DENSITY; BONE DISEASE; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; HUMAN; IDIOPATHIC DISEASE; LUMBAR SPINE; MALE; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; VERTEBRA FRACTURE;

ADULT; AGED; AMINO ACIDS; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; BONE RESORPTION; CALCITONIN; COLLAGEN; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PEPTIDES;

EID: 0036183610     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2002.17.3.521     Document Type: Article

References (27)

1. Management of male osteoporosis: Report of the UK Consensus Group
2. Aetiology in male osteoporosis
3. Aetiology and presenting symptoms in male osteoporosis
4. Severe osteoporosis in men
5. Epidemiology of fractures
6. Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures
7. Treatment of osteoporosis (osteopenia) in adult men with disodium etidronate
8. Response of males with osteoporosis to intermittent cyclical therapy with etidronate/calcium over 3 to 5 years
9. Randomized controlled trial of APD (disodium pamidronate) given intravenously with and without sodium fluoride in involutional osteoporosis
10. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD
11. Alendronate for the treatment of osteoporosis in men
12. Avoidance of vertebral dose intermittent monofluorophosphate
13. Prevention of bone loss in early non-surgical and non-osteoporotic high turnover patients with salmon calcitonin: The role of biochemical markers in monitoring high turnover patients under calcitonin treatment
14. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: A dose-response study
15. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss
16. Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study
17. Effect of different doses of nasal salmon calcitonin on bone mass
18. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study
19. Calcitonin treatment of osteoporosis
20. Bone density at various sites for prediction of hip fractures
21. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
22. Bone resorption markers predict hip fracture risk in elderly women: The EPIDOS prospective study
23. Case-control analysis of bone resorption markers, disability, hip fracture risk: The Rotterdam study
24. Changes in BMD substantially underestimate the anti-fracture effect of alendronate and other antiresorptive drugs
25. The effect of 2 and 3 years of raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis
26. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis
27. Advances in the study of osteoporosis in men